Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbmV4NWgtNHIxcFNOYk8tdEdrZVQ2cmdKQUJsWG12bUszbXVLN3NJZWo1VnowM0NocTVPb3RtQ2dSWE5JeXJiRnF4RkR4LVlGcEtrZHRTWUxnS3UyajM3QUlUbDVhZ0pqZWdCSE5QRS1QTE9BekIyTlF2OFZqZFF0SHZCaHZVTHZ3amRfd3VUdGZUSUlsQm9jZDg5M3FHaDBDdGFkc1hFM0t3U1N6SkxvamppdUMyVmFicHA0VDZDSQ?oc=5" target="_blank">Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say</a> <font color="#6f6f6f">Reuters</font>
Inhibrx Biosciences is exploring a joint spin-off of its experimental cancer drug, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The potential valuation of the drug could exceed $8 billion if clinical trials confirm its efficacy.
Merck & Co, Germany's Merck KGaA, and Japan's Ono Pharmaceutical are reportedly interested in Inhibrx's experimental cancer treatment, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The drug could be valued at over $8 billion if clinical trials are successful.
Similar Stories
Related coverage based on topic and tags
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy - Reuters
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy Reuters
August 24, 2026 at 07:11 AMBristol Myers ends blood cancer drug deal with cell therapy maker Cellares - Reuters
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares Reuters
August 25, 2026 at 06:00 PMSuccess after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough - Reuters
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough Reuters
August 28, 2026 at 11:32 AMUS FDA approves Takeda, Protagonist's drug for rare blood cancer - Reuters
US FDA approves Takeda, Protagonist's drug for rare blood cancer Reuters
August 28, 2026 at 10:16 PMAstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
August 27, 2026 at 06:10 AMThe Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use? - Reuters
The Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use? Reuters
August 25, 2026 at 04:32 PM